Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study.

Trial Profile

Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Monoclonal antibody 3F8 I-131 (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 02 Mar 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2016 according to ClinicalTrials.gov record.
    • 02 Mar 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2016 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top